CPT1A and head and neck squamous cell carcinoma: Genetic depletion of mutant FAT1 or treatment with the CPT1A‐specific inhibitor ST1326 significantly improved the antitumor efficacy of CPI‐613, suggesting that FAT1‐CPT1A signaling may facilitate a metabolic bypass that attenuates the effectiveness of CPI‐613 in HNSCC.